Trial Profile
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Multicenter Study to Evaluate the Safety and Efficacy of CLS001 Topical Gel Versus Vehicle Applied Once Daily for 12 Weeks to Female Subjects With Moderate to Severe Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2019
Price :
$35
*
At a glance
- Drugs Omiganan (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Cutanea Life Sciences
- 21 Sep 2016 Status changed from recruiting to completed.
- 14 Oct 2015 New trial record